ClinicalTrials.gg
RecruitingNCT05240001Updated Aug 16, 2024

Thulium Fiber Laser (TFL) vs Holmium MOSES for Treatment of Benign Prostatic Hyperplasia (BPH)

An interventional study of Thulium Fibre Laser and MOSES Holmium Laser in Benign Prostatic Hyperplasia, sponsored by Thunder Bay Regional Health Research Institute. Recruiting at 1 site in Canada. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Thunder Bay Regional Health Research Institute · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies in Prostatic Hyperplasia with a site in Canada — 11 open to participants now, 16 under way, 3 of them phase 3. Prostatic Hyperplasia · Canada.

Planned enrollment
26th of 47
104 · median 108
Started
2022
with 1 other
No phase
19 of 53
7 open now
Primary completion
2025-04
later than 6 of 15 live
Registered
44th of 53
by date
Lead sponsor
4 of 53
Thunder Bay Regional Health Research Institute

Among the 53 studies in Prostatic Hyperplasia with a site in Canada, this one is the 26th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2022, is one of 19 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 44th registered.

Prostatic Hyperplasia

830 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

11 of the 53 studies in Prostatic Hyperplasia with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Prostatic Hyperplasia with a site in Canada, or all of them as a file.
02

Study summary

Benign prostatic hyperplasia (BPH), the non-cancerous enlargement of the prostate, places pressure on the urethra and causes urination and bladder problems. Transurethral Resection of the Prostate (TURP) remains the gold standard treatment in most centres for BPH. However, morbidity after TURP is high, especially bleeding requiring blood transfusion and late postoperative bleeding.

Holmium laser enucleation of the prostate (HoLEP) is a safe and effective procedure which has demonstrated comparable results to TURP. HOLEP also offers patients the alternative of being treated endoscopically with minimal blood loss, short catheterization time, and decreased hospital stay. The main reason HoLEP has yet to become the new standard for treatment of symptomatic BPH is due the complexity of this procedure as compared to TURP. Furthermore, the HoLEP can be used with the MOSESTM system, a system that allows for more efficiency and ease of use of the HoLEP.

Thulium fiber laser (TFL) enucleation of the prostate is an emerging technology for endoscopic prostate enucleation that is notable for its high wavelength and pulsed mode of action. Recent studies have shown TFL enucleation of the prostate to be a safe and highly efficacious treatment modality for the management of large volume (> 80 cm3) glands in BPH. Due to its novelty, further studies are needed to broaden the investigators' understanding of the TFL and comprehend the full implications and benefits of this new technology, as well its limitations.

The aim of this study is to whether Thulium Fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation using MOSES™ (M-HoLEP) have comparable length of hospital stay, as well as intraoperative and postoperative outcomes.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males over 50 years of age at the time of enrollment
  2. Referred to urology for LUTS or urinary retention secondary to BPH
  3. Failed medical (non-surgical) treatment
  4. Prostate size on preoperative TRUS of≥80 ml
  5. IPSS >15 and QOL score ≥3 and Qmax \<15 ml/sec
  6. Written to participate in the study
  7. Ability to comply with the requirements of the study procedures

Exclusion criteria

Exclusion Criteria:

  1. Previous surgical treatment for BPH
  2. History of prostate cancer
  3. Prostate size \< 80 mL
  4. History of urethral stenosis or its management
  5. Known or suspected neurogenic bladder
  6. Participants with active urinary tract infection until appropriately treated
  7. Participants with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study
  8. Participants who lack the capacity, or cannot speak English, in order to provide free and informed written consent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Thulium Fibre Laser (TFL)

    Patients randomized to this arm will undergo treatment using the TFL.

    Device: Thulium Fibre Laser

  • Experimental
    MOSES Holmium Laser

    Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.

    Device: MOSES Holmium Laser

Interventions

  • DeviceThulium Fibre Laser

    Participants will undergo treatment using the TFL

  • DeviceMOSES Holmium Laser

    Participants will undergo treatment using the MOSES Holmium laser.

06

What researchers measure

Primary outcomes

  1. Length of stay in the hospital

    Time frame: within 6 hours

Secondary outcomes

  1. Incidence of bleeding

    Time frame: Intra-Op

  2. Incidence of blood transfusion

    Time frame: Intra-Op

  3. Operative time

    Including laser use time

    Time frame: Intra-Op

  4. International Prostate Symptom Score

    Eight questions (seven concerning urinary symptoms and one concerning quality of life), responses range from 0 (better outcome) to 5 (worse outcome), with total score ranging from 0 to 35.

    Time frame: 1,3,6,12 months post-op

  5. Quality of Life (QOL) as scored on the International Prostate Symptom Score (IPSS)

    Response to the last question on the IPSS: "If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?" Response ranging from 'Delighted' to 'Terrible'.

    Time frame: 1,3,6,12 months post-op

  6. Peak flow rate

    Qmax

    Time frame: 1,3,6,12 months post-op

  7. Post-void residual

    PVR

    Time frame: 1,3,6,12 months post-op

  8. Prostate specific antigen

    PSA

    Time frame: 1,3,6,12 months post-op

  9. Change in size

    Assessed by TRUS

    Time frame: 6 months

  10. Time to Catheter Removal

    Time frame: within 4 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2025, 36 months after the start.

Of 153 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 205 studies reached it within 26 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2022
First posted
Feb 15, 2022
StartActual
Apr 20, 2022
Primary completionEst.
Apr 2025
CompletionEst.
Dec 2025
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05240001
Lead sponsor
Thunder Bay Regional Health Research Institute
Responsible party
Hazem Elmansy (Urologist, Thunder Bay Regional Health Research Institute) — Principal investigator
First posted
Feb 15, 2022
Start date
Apr 20, 2022
Primary completion
Apr 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 16, 2024

Study contacts

Rabail Siddiqui, MPH, MHSc
Contact
siddiqur@tbh.net
(807) 684-6608
Hazem Elmansy, MD
Contact
Hazem Elmansy, MD
principal investigator · Thunder Bay Regional Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion